Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-Methyl–5-(7-{4-[ (4R)–4-methyl–4,5-dihydro–1,3–oxazol–2‑yl ]phenoxy }heptyl )‑1,2‑oxazole** is a synthetic small molecule belonging to the phenol ethers chemical class. It features an oxazole and oxazoline moiety connected via a heptyl linker to a phenoxy group. The compound is listed in several chemical and drug databases (PubChem CID: 5272139; DrugBank ID: DB08727; ChEMBL ID: CHEMBL55483). It is described as experimental with no approved medical indications or clinical trials reported. Its only known molecular target is the "genome polyprotein," suggesting it may have been investigated for antiviral activity or as a research tool targeting viral polyproteins[1][6][2]. No pharmacological mechanism of action or therapeutic use has been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole.